The aggressiveness of glioblastoma multiforme (GBM) is defined by local invasion and resistance to therapy. Within established GBM, a subpopulation of tumor-initiating cells with stem-like properties (GBM stem cells, GSCs) is believed to underlie resistance to therapy. The metabolic pathway autophagy has been implicated in the regulation of survival in GBM. However, the status of autophagy in GBM and its role in the cancer stem cell fraction is currently unclear. We found that a number of autophagy regulators are highly expressed in GBM tumors carrying a mesenchymal signature, which defines aggressiveness and invasion, and are associated with components of the MAPK pathway. This autophagy signature included the autophagyassociated genes DRAM1 and SQSTM1, which encode a key regulator of selective autophagy, p62. High levels of DRAM1 were associated with shorter overall survival in GBM patients. In GSCs, DRAM1 and SQSTM1 expression correlated with activation of MAPK and expression of the mesenchymal marker c-MET. DRAM1 knockdown decreased p62 localization to autophagosomes and its autophagy-mediated degradation, thus suggesting a role for DRAM1 in p62-mediated autophagy. In contrast, autophagy induced by starvation or inhibition of mTOR/PI-3K was not affected by either DRAM1 or p62 downregulation. Functionally, DRAM1 and p62 regulate cell motility and invasion in GSCs. This was associated with alterations of energy metabolism, in particular reduced ATP and lactate levels. Taken together, these findings shed new light on the role of autophagy in GBM and reveal a novel function of the autophagy regulators DRAM1 and p62 in control of migration/invasion in cancer stem cells.
INTRODUCTION
Glioblastoma multiforme (GBM) represents one of the leading cancer-related deaths in both the pediatric and adult populations, with median survival being on average little over a year. This dismal prognosis is caused by different factors. First, the intrinsic capacity of isolated tumor cells to invade the surrounding parenchyma makes surgical resection an insufficient therapy in nearly all cases. Second, intrinsic or acquired resistance to conventional and targeted therapy further complicates treatment of GBM. In this respect, a subpopulation of cancer cells with stem cells properties (glioblastoma stem cells, (GSCs)) has been proposed to underlie resistance to therapy in established GBM, thus promoting tumor regrowth and disease relapse. 1 GSCs not only generate neural cell types but they are also able to transdifferentiate to tumor endothelial cells. 2, 3 As a result, intense efforts are now being directed towards identifying therapeutic strategies that could target these cells. Finally, tumor heterogeneity poses a barrier against effective therapy. Recent studies have demonstrated that GBM can be classified into multiple molecular subtypes on the basis of their gene expression profiles. 4 --6 One of these subtypes is characterized by the expression of mesenchymal and angiogenic genes. Patients belonging to the mesenchymal subtype have the worst prognosis. Interestingly, suppression of the mesenchymal signature severely impairs tumor invasion and progression in preclinical models, 7 thus suggesting that this signature may enhance the invasive capacity of GBM cells. These studies suggest that therapy directed against these distinct molecular features could represent significant advance in GBM treatment. However, limited evidence is available on whether these signatures are retained in primary tumor cells derived from GBM.
Metabolic reprogramming is a hallmark of cancer and has been proposed to provide new druggable targets. 8 Alterations of cellular bioenergetics and redox mechanisms have been implicated in tumor development and progression. In particular, mutations of the isocitrate dehydrogenase genes (IDH1 and IDH2), which are involved in the tricarboxylic acid cycle, have been found in GBM and acute myeloid leukemia. 9, 10 In established tumors, maintenance of cellular bioenergetics becomes particularly important when tumor cells are exposed to stress, such as starvation, hypoxia and chemo/radiotherapy. These stressors activate the metabolic autophagy pathway. Autophagy is an evolutionary conserved, intracellular degradation mechanism, based on the formation of a double-membrane vesicle called the autophagosome (AP). The AP engulfs intracellular components, such as membranes and organelles, which are subsequently degraded upon fusion with the lysosome. It is required to produce metabolic intermediates for energy production/biosynthesis and disposal of toxic metabolites/damaged organelles. 11 --13 In addition, autophagy is used for targeted degradation of ubiquitylated proteins through a mechanism involving cargo-binding proteins, such as the ubiquitin-binding factor p62 (encoded by SQSTM1), a scaffold protein at the crossroad between autophagy and signaling. 14, 15 In this respect, p62 regulates the targeting of dysfunctional mitochondria to the AP via a process called mitophagy. 14, 15 While during tumor initiation autophagy has been proposed to have a tumor suppressive role by limiting genomic instability and inflammation, established cancers use autophagy to promote survival. 14, 16, 17 In particular, autophagy may contribute to tumor dormancy and resistance to therapy. 14, 17, 18 Autophagy is an emerging target for cancer therapy. 19, 20 In this respect, our group has found that in chronic myeloid leukemia, pharmacological inhibition of autophagy using the anti-malaria drug and autophagy inhibitor chloroquine (CQ) sensitizes tumorinitiating cells to targeted therapy. 20 --22 Our study on chronic myeloid leukemia has led to a Phase II clinical trial for the use of hydroxychloroquine in combination with targeted therapy (http:// www.controlled-trials.com/ISRCTN61568166). Notably, CQ has been shown to increase survival and the efficacy of conventional treatment in GBM patients in two randomized trials and a retrospective study. 23 --25 Furthermore, a trial for the use of hydroxychloroquine in combination with radiation and temozolomide in GBM is currently ongoing (http://clinicaltrials.gov/ ct2/show/NCT00486603?term ¼ hydroxychloroquine+cancer&rank ¼ 17). This is one of over 20 trials for the use of autophagy inhibitors in cancer therapy that have been activated in the last few years (http://clinicaltrials.gov/ct2/results?term ¼ hydroxychloroquine+ cancer). Autophagy induction has been implicated in GBM in the response to radiotherapy, temozolomide, as well as targeted therapies.
26 --35 AP/autolysosome (AL) accumulation has been detected in temozolomide-treated malignant GBM. 36 Although these studies suggest that autophagy may regulate progression in GBM, a systematic analysis of the autophagy status in these tumors is missing. In this respect, differences in expression of autophagy regulators across GBM molecular subtypes could affect the response to autophagy inhibition. Importantly, it is still unclear what role(s) this metabolic pathway plays in GSCs (see above).
Here we show that a number of autophagy regulators are highly expressed in adult GBM tumors belonging to the mesenchymal subtype and displaying a MAPK signature. These include DRAM1 and p62. Knockdown (KD) of DRAM1 and p62 in GSCs leads to alterations of cellular bioenergetics and inhibits migration/invasion. DRAM1 regulates autophagosomal association of p62 and its autophagymediated degradation. Overall, these findings implicate the autophagy-associated proteins DRAM1 and p62 in the regulation of energy metabolism and cancer cell migration/invasion in GBM.
RESULTS
Overexpression of autophagy-associated genes in the mesenchymal subgroup of GBM Several lines of evidence suggest that autophagy may be instrumental for tumor progression in established cancers, including GBM. However, very little is known about the status of autophagy in primary tumors. We set out to investigate expression of autophagy genes in a series of adult GBM samples for which gene expression data was publicly available. 4 --6,37 Genes were selected based on a recent proteomic study detailing key components of the autophagic machinery 38 (Supplementary Table 1 ). In total, 467 cases of primary glioblastoma were subclassified according to the Phillips 6 schema as 'proneural', 'proliferative' or 'mesenchymal' on the basis of their gene expression signatures, and probed for subclass-specific associations with autophagy genes included in Supplementary Table 1 ( Figure 1 and Supplementary Figure 1) . We found an enrichment of autophagy genes in the mesenchymal subgroup ( Figure 1 ). Most significant associations included DRAM1, 39, 40 SQSTM1 (encoding p62---see introduction 14 ), WIPI1 and ATG7 (Figure 1c and not shown). We next probed for associations between expression of autophagy regulators and clinical/pathological correlates. We identified high levels of DRAM1 expression to correlate with a shorter overall survival time across all subclasses and within the mesenchymal subtype in particular (Figure 1d ). DRAM1 was originally implicated as a p53 target gene and regulator of autophagy. 39, 40 It was reported to associate with the lysosome, thus suggesting that it may act on late steps of the autophagic process. However, its precise function is still undefined.
Association between the RAS/MAPK pathway and autophagy in primary tumors and GBM stem cells One of the questions arising from our initial observation was whether the expression of autophagy genes could be associated with specific signaling pathways in GBM. First, re-examining the gene expression data, we noted strong positive correlations between FOSL1 and FOSL2 and the mesenchymal subclass (Figures 2a and b) , as previously suggested. 7 The FOSL1 and FOSL2 transcription factors are key components of the RAS/MAPK signal transduction pathway, which is activated in GBM downstream growth factor (GF) receptors and through mutation or downregulation of its negative regulator neurofibromatosis type 1-associated neurofibromin1 gene (NF1). 41 Notably, NF1 gene expression is downregulated mainly in tumors belonging to the mesenchymal subtype.
41 --43 Accordingly, we found a significant negative correlation between tumors overexpressing FOSL1/FOSL2 and NF1 expression (Figure 2b ). Given the association between the mesenchymal subclass and autophagy regulators, we performed a regression analysis to determine the degree of coexpression of these genes. Significant positive associations were observed between autophagy genes and the transcription factors FOSL1 and FOSL2 (Figure 2c ). In contrast, a negative association with NF1 expression was revealed (Figures 2b and c) . Overall, this analysis suggested that a functional association between the RAS/MAPK pathway and autophagy might exist.
We decided to investigate the potential link between autophagy and the MAPK pathway in GBM cells. We chose to use GBM cells isolated from primary surgical specimens via culturing in neural stem cell (NSC) medium in the presence of epidermal GF (EGF) and fibroblast GF 2. 44 These cells carry stem-like features and bear tumor-initiating capacity 44 (data not shown) and can be defined as GBM stem cells (GSCs). They were not selected using surface markers such as CD133, thus avoiding problems related to reliability of reagents for sorting. We decided to use adherent conditions, following established protocols. 44 Apart from their cancer stem cell features, GSCs are clearly a more reliable model closer to tumor of origin and superior to established GBM lines. We used four GSC lines displaying variable levels of ERK phosphorylation as readout for activation of the RAS/MAPK pathway ( Figure 2d ). Increased ERK phosphorylation also associated with higher expression of the hepatocyte GF receptor (c-MET), which is part of the gene expression signature used to identify the mesenchymal GBM subtype and acts as inducer of RAS and metastatic behavior 45 ( Figure 2d ). This suggests that GSCs can present some of the associations described in primary tumors.
We then tested whether ERK activation and c-MET expression correlated with autophagy induction in GSC lines. Indeed, the extent of LC3 lipidation upon inhibition of the PI-3K/mTOR pathway was higher in RAS/MAPK high GSC lines (Figure 2e ). PI-103 had no effect on ERK phosphorylation (not shown). In RAS/ MAPK high G166 cells, treatment with the MEK inhibitor U0126 reduced PI-103-mediated induction of autophagy (Figure 2f ). Overall, these data suggest that the RAS/MAPK pathway may positively modulate autophagy in GSCs, as suggested for other cancer types. 46 --48 This could be in part through transcriptional control, as U0126 reduced the expression of DRAM1 and FOSL1 in G166 cells (Supplementary Figure 2) . To determine whether RAS activation can influence autophagy in normal NSCs, we overexpressed an oncogenic form of RAS (hRAS-V12) in primary mouse NSCs. hRAS-V12 induced the expression of FOSL1 as well as of DRAM1 and the SQSTM1 (Supplementary Figure 3a, b) . p62 (encoded by SQSTM1) expression was clearly upregulated in extracts from hRAS-V12 cells (Supplementary Figure 3c) . We could not analyze DRAM1 because of the absence of reliable antibodies. While basal autophagy was not affected in hRAS-V12-expressing NSCs, both starvation-and PI-103-induced autophagy were increased (Supplementary Figure 3d) . Together, these findings suggest that autophagy is associated with and may be regulated by RAS/MAPK activation in GSCs.
The autophagy-associated factor DRAM1 regulates autophagosomal association of p62 We initially focused on DRAM1 because of its association with poor overall survival in GBM patients. Among the four GSC lines, DRAM1 was highly expressed in the RAS/MAPK high , MET high G166
and G2 cells (Figure 3a) , again suggesting that correlations observed in patients may be retained in GSCs. Notably, also SQSTM1 expression displayed similar associations (Figure 3a) . In order to gain insights into the function of DRAM1 and p62 in GSCs, we transduced G166 cells with lentiviral vectors expressing shRNAs against DRAM1, p62 or a Scramble shRNA (Figures 3b and c) . DRAM1 KD G166 cells (shDRAM1.1) showed a moderate increase in cell growth (Supplementary Figure 4a ). shDRAM1.2 had similar effects (not shown). Notably, KD of p62 also promoted cell growth, which was more marked compared with DRAM1 KD (Supplementary Figure 4b) . We next sought to determine the potential relationship between DRAM1 and p62. As p62 is involved in selective autophagy, we set out to investigate whether DRAM1 could regulate p62 association with LC3, an index of p62-mediated autophagy. As p62 is degraded along with its targets in the AL, we treated Scramble and DRAM1 KD with CQ in order to enhance the showing the effects on overall survival of overexpression of DRAM1 (purple) in 437 GBM for which clinical outcome data was available (P ¼ 0.011, log-rank test). Kaplan --Meier curve (right panel) showing the effects on overall survival of overexpression of DRAM1 (purple) in mesenchymal subtype for which clinical outcome data was available (P ¼ 0.026, log-rank test; right panel).
detection of p62-labeled APs/ALs. As shown in Figure 3d , DRAM1 KD resulted in a significant decrease in p62/LC3 colocalization. Furthermore, we tested whether DRAM1 KD impinged on autophagosomal degradation of p62. While in Scramble cells CQ-mediated inhibition of (auto)lysosomal degradation increased p62 levels, this effect was significantly impaired in DRAM1 KD cells ( Figure 3e ).
We then analyzed whether DRAM1 and p62 regulate nonselective autophagy in GSCs. As previously suggested, 49 p62 KD did not affect basal nor starvation-induced autophagy (Figure 3f ). PI-103-induced autophagy was similarly unaffected (Figure 3f ). DRAM1 KD in GSCs also failed to impair basal, starvation-or PI-103-induced autophagy (Figure 3f ). However, as previously suggested, 39, 40 DRAM1 overexpression in HEK293T cells induced autophagy ( Supplementary Figure 4c, d ). This effect may be related to the overexpression system used or to differences in experimental models. We then generated stable GSC lines expressing shRNAs against the essential autophagy genes ATG5 and ATG7 ( Figure 3g ). As expected, downregulation of ATG5 and ATG7 impaired autophagy, both at steady state and upon starvation or PI-103 treatment ( Figure 3g ). Unlike DRAM1 and p62 KD, ATG7 and ATG5 downregulation did not have substantial effects on cell growth (Supplementary Figure 4e and not shown). Taken together, these data suggest that DRAM1 may regulate p62 autophagic function, but, like p62, is not required for non-selective autophagy.
DRAM1 and p62 regulate energy metabolism in GBM stem cells As autophagy has been implicated in maintenance of cellular bioenergetics in RAS/MAPK high cancer cell lines, 46, 48 we set out to investigate the effect of stable DRAM1 or p62 KD on energy metabolism. Indeed, we could demonstrate a significant reduction in ATP levels in both DRAM1 and p62 KD cells (Figure 4a ). ATG7 and ATG5 KD produced similar effects ( Figure 4a ). As reduced ATP production in autophagy-impaired cells has been linked to defective mitochondrial bioenergetics, 46 we analyzed whether the decrease in ATP levels correlated with reduced oxygen consumption rate (OCR), an index of electron transport chain activity. However, OCR was unaltered in DRAM1 KD cells and even moderately increased in p62 KD cells (Figure 4b ). This latter effect was phenocopied by ATG7 KD (Figure 4b ). The mitochondrial membrane potential (DC m ), an important parameter of mitochondrial physiology, was also unaffected in DRAM1 and p62 KD cells in basal conditions (not shown). However, oligomycinmediated inhibition of the F 1 Fo-ATP synthase enzyme led to specific alterations of DC m (Figure 4c ). While in Scramble cells oligomycin treatment produced a rise in fluorescence caused by the blockage of H þ flux in the matrix, in DRAM1 and p62 KD cells we observed a decrease of fluorescent signal. These data suggest that despite normal OCR, the F 1 Fo-ATP synthase is dysfunctional in DRAM1 and p62 KD GSCs (Figure 4c ). These changes were accompanied by alterations of mitochondria morphology. While most Scramble cells displayed fragmented mitochondria clustered around the nucleus, in DRAM1 KD cells mitochondria acquired a tubular phenotype (Figure 4d ; Supplementary Figure 5) . Downregulation of p62 led to similar changes (Figure 4d ). Defective autophagic degradation of dysfunctional mitochondria (mitophagy) can trigger mitochondrial fusion as protective mechanism. 50, 51 Notably, alterations of p62-mediated mitophagy have been suggested to underlie bioenergetic defects of autophagy-impaired RAS/MAPK high cells. 46 It is therefore possible that diminished p62-mediated selective autophagy could lead to mitochondrial fusion in GSCs, which would in turn limit detrimental effects on oxidative phosphorylation. One of the possible explanations for the drop in ATP levels could be reversion of the F 1 Fo-ATP synthase, as suggested by our data on DC m upon oligomycin treatment (see Figure 4c ). This could be linked to a defect in mitochondrial coupling. 52 However, reduced glycolysis could also contribute to the bioenergetic defects of DRAM1 and p62 KD cells. In this respect, previous studies have suggested that autophagy impairment negatively affects glycolysis. 47,53 --55 Notably, this decrease has been associated with impaired p62 degradation. 55 We explored potential effects on glycolysis by measuring lactate levels in Scramble, DRAM1 and p62 KD cells. Indeed, lactate levels were decreased in DRAM1 and p62 KD cells (Figure 4e ). Inhibition of autophagy via KD of ATG5 and ATG7 led to similar defects (Figure 4e ). Taken together, these data suggest that DRAM1 and p62 regulate energy metabolism in GSCs.
Autophagy is induced in actively migrating and invading GSCs The mesenchymal signature confers high invasive properties to GBM primary cells in vitro as well as in orthotopic xenografts. 7 Therefore, it is conceivable that autophagy genes, as part of the mesenchymal signature, could be involved in regulation of migration/invasion. Previous studies have suggested a role of autophagy in regulating survival upon detachment from the substrate in cancer cells displaying activation of RAS. 47, 56, 57 This effect was associated with modulation of glycolysis. 47, 54 In this respect, glycolytic metabolism has been proposed to fuel cancer cell invasion, including GBM. 58 --60 We first investigated whether autophagy was increased in GSCs invading through extracellular matrix. We plated GSCs in matrigel inserts and analyzed endogenous LC3 at different time points from plating. As shown in Figure 5a , very few LC3 þ puncta were detected at days 1 and 3, when most cells have not started migrating into matrigel. In contrast, most invading cells displayed many LC3 þ APs/ALs at days 7 and 10 ( Figure 5a ). Notably, we could detect localization of p62 in LC3 puncta, thus suggesting that p62-mediated autophagy is increased in these conditions (Figure 5a ). Furthermore, analysis of LC3-GFP puncta revealed a clear increase in LC3-GFP þ cells and number of LC3-GFP puncta/cell in both fixed or live cells grown in matrigel compared with cells plated on laminin (Figures 5b and c and not shown) . CQ increased the number of LC3-GFP puncta/cell in both conditions, with invading cells showing the greater number (Figure 5b and not shown). The lack of induction of LC3 puncta early after plating on matrigel suggests that autophagy is induced in invading cells rather than upon simple exposure to extracellular matrix. To test this, we analyzed LC3-GFP puncta in cells plated on laminin-, collagen I-or BD Matrigel-coated coverslips (BD Bioscience, Franklin Lakes, NJ, USA). Indeed, adhesion to either collagen-I or BD Matrigel was not sufficient to activate autophagy (Supplementary Figure 6) . Finally, we analyzed LC3-GFP puncta induction in wound healing experiments. LC3-GFP þ cells close to the wound displayed a clear increase in LC3-GFP puncta, whereas LC3-GFP signal was rarely detected in puncta in cells far from the wound (Figure 5d ). DRAM1 and p62 regulate cell motility and invasive properties of GSCs Having established that autophagy is induced in actively invading/ migrating GSCs, we set out to determine whether KD of DRAM1 and p62 affected migration and/or invasion. We first utilized the Incucyte platform to study migratory properties of GSCs upon downregulation of DRAM1 in wound healing experiments. Both shRNA sequences against DRAM1 significantly reduced wound closure compared with Scramble cells (Figure 6a) . Downregulation of ATG7 inhibited wound closure to a similar extent (Figure 6b ). Similar changes were observed in ATG5 KD cells (Figure 6c ). In contrast, p62 KD did not impair migration (Figure 6d ). We reasoned that this could be ascribed to the increased growth properties of p62-depleted cells, a confounding factor in wound healing experiments. To test this, we performed wound closure assays in the absence of GFs. In these conditions, G166 cells became cell cycle arrested without acquiring lineage-specific markers (not shown). In GF-deprived GSCs, downregulation of p62 led to decreased wound closure to similar extent as DRAM1 and ATG7 KD (Figure 6e ).
We next analyzed the effect of suppression of autophagy regulators on invasion by using invasion chambers. DRAM1 and p62 KD clearly decreased invasive capacity of GSCs (Figure 7a ). This effect was phenocopied by KD of the essential autophagy regulator ATG7 (Figure 7b) . Similarly, pharmacological inhibition of (auto)lysosomal function using CQ led to impaired invasion (Figure 7c) . Finally, the MEK inhibitor U0126 suppressed LC3 puncta formation in GSCs grown in matrigel (Supplementary Figure 7) , thus suggesting that MAPK signaling positively modulates autophagy induction in invading cells.
DISCUSSION
The main findings of our study are: (i) high expression of autophagy-associated factors, such as DRAM1 and p62, is found in GBM patients belonging to the mesenchymal subclass, 6, 43 which defines aggressiveness and invasion; 7 (ii) DRAM1 expression correlates with poor overall survival; (iii) in primary tumors and GSCs, autophagy is associated with activation of the RAS/MAPK pathway; (iv) DRAM1 and p62 regulate energy metabolism and cell migration/invasion in GSCs.
Our work shows that patients expressing the autophagy inducer DRAM1 have a significantly shorter survival. DRAM1 was originally identified as the target gene of wild-type and mutant p53, and regulator of p53-triggered autophagy. 39, 40 However, its precise role in autophagy was still unclear. There was no correlation between DRAM1 expression and p53 mutational status in the GSC lines used for this study (not shown), thus arguing against a p53-dependent control of DRAM1 expression. Instead, our data indicate that the expression of DRAM1 and p62 in GBM could be controlled at least in part by the RAS/MAPK pathway. More in general, levels of autophagy directly correlate with ERK phosphorylation in GSC lines, and MAPK inhibition impairs autophagy induction. Recent work from Eileen White's group and others 46 --48 reported an association between RAS signaling and autophagy in tumor cell lines, which is required for promoting survival. Furthermore, another study reported MAPK-dependent induction of autophagy upon expression of activated RAS in mesenchymal stem cells. 61 More in general, these findings suggest that some of the gene expression signatures and related associations identified in the bulk of the tumor are retained in GSCs. This could reflect similarities between bulk tumor cells and GSCs. Alternatively, the proportion of tumor cells with cancer stem cells features in the bulk of the tumor could be higher than previously thought or their identity being more blurred. The paucity of reliable markers for quantification of tumor cells with stem properties within the tumor does not allow us to reach firm conclusions in this respect.
What would be the role of DRAM1 and p62 in GSCs? Our findings show that p62, as previously reported for other cellular models, is dispensable for induction of non-selective autophagy in GSCs. Similarly, KD of DRAM1 failed to affect this type of autophagy. In contrast, DRAM1 KD led to a decreased autophagosomal association and AP-mediated degradation of p62, suggesting that p62-mediated selective autophagy may be impaired. These changes were accompanied by reduction in ATP levels in basal conditions, suggesting that DRAM1 regulates energy metabolism in GSCs. Similar changes were observed upon stable p62, ATG5 or ATG7 downregulation. It is therefore conceivable that DRAM1 could regulate cellular bioenergetics by affecting p62-mediated autophagy. In this respect, autophagy is known to regulate mitochondria bioenergetics in epithelial cancer cells displaying constitutive activation of the RAS/MAPK signaling. 46, 48 This function is potentially exerted through regulation of mitochondria quality control, which in part relies on the p62 cargo.
14, 46 Notably, activation of RAS signaling can induce mitophagy, although the underlying mechanisms are still unclear. 53 For this reason, we investigated mitochondria morphology and function upon DRAM1 or p62 downregulation. Our data show that both DRAM1 and p62 KDs affect mitochondria morphology in GSCs. In particular, they cause a mitochondrial tubular phenotype, suggesting an increase in mitochondrial fusion. Previous studies have proposed that defective mitophagy can trigger fusion to limit mitochondria dysfunction as protective mechanism. 50, 51 In agreement with this, neither OCR or mitochondria membrane potential is affected by DRAM1 or p62 KD, thus suggesting that increased fusion may maintain oxidative metabolism. However, pharmacological inhibition of the F1-Fo ATP synthase in DRAM1 and p62 KD cells fails to increase the mitochondrial membrane potential, as observed in Scramble cells. Instead, it causes a slow decline. This effect could be due to dysfunctional ATP synthase activity and in particular to its reverse activation, which would reduce ATP levels, as observed in DRAM1 and p62 KD cells. Our data suggest that additional mechanisms could also contribute to the decreased ATP levels. In this regard, DRAM1 and p62 KD cause a reduction in lactate levels. Similar changes were observed upon ATG5 and ATG7 downregulation. GBM cells are known to contain high levels of glucose transporters and display active glycolysis. 62 --70 Previous studies have suggested that autophagy regulates glycolysis, 47, 53, 55 potentially via modulation of glucose uptake. 47, 55 Alterations of glucose uptake could indeed be one of the mechanisms underlying the decreased lactate levels. However, we cannot exclude that degradation of key metabolic factors via selective autophagy could have a part. Further investigation is needed to fully dissect the role of DRAM1 and p62 in regulation of energy metabolism in GSCs.
Glycolysis has been associated with cancer cell invasion, including GBM. 58 --60 Furthermore, autophagy regulates survival upon detachment from the substrate in cancer cells displaying activation of RAS, 47, 56, 57 an effect associated with modulation of glycolysis. 47, 54 Interestingly, high levels of enzymes involved in the energy-producing portion of the glycolytic pathway are found in GBM cell pseudopodia, thus suggesting that enhanced glycolysis may aid migration in GBM. 58 Our data clearly show that suppression of either DRAM1 or p62 expression inhibits invasion and migration in GICs. This effect is phenocopied by KD of the essential autophagy regulators ATG5 and ATG7 as well as by treatment with the (auto)lysosomal inhibitor CQ. APs/ALs are increased in invading cells, thus suggesting that autophagy may have a role in fueling invasion. In this respect, it is conceivable that DRAM1 and p62 could contribute to autophagy-dependent targeting/degradation of metabolic components and/or dysfunctional organelles. This might in turn modulate the invasive/ migratory properties of GSCs. It is interesting to note that a correlation between fused mitochondrial morphology and impaired migration has been reported also for T cells, thus suggesting that changes in mitochondrial morphology observed in DRAM1 and p62 KD GSCs could at least in part underlie the observed migration/invasion defects. 71 Overall, this work establishes a novel role for the autophagy regulators DRAM1 and p62 in controlling invasion and migration in GSCs potentially through regulation of energy metabolism. It is therefore possible that autophagy could assist spreading of cancer stem cells within the brain parenchyma. Furthermore, given the reported pro-invasive effect of irradiation in GBM cells, 72 --74 inhibition of autophagy could enhance the efficacy of radiotherapy not only by acting through limitation of survival. Further studies will address the role of autophagy in promoting invasion in preclinical models of GBM. More generally, this work could lead to the identification of valuable autophagy biomarkers with prognostic/ predictive value. In this respect, it is conceivable that susceptibility to autophagy suppression could vary depending on expression of autophagy regulators across the different GBM subclasses.
MATERIALS AND METHODS

Bioinformatics analysis
Publicly available gene expression data for a series of pediatric 5 and adult 4, 37 primary GB samples profiled on Affymetrix U133 (Affymetrix, Santa Clara, CA, USA) platforms were downloaded and integrated in R 2. 11 (http://www. r-project.org/). CEL files were read using the Affymetrix package of BioConductor 2.6, and normalized for each study using the robust multichip average (rma) algorithm. 75 Common probesets across the respective studies and platforms were extracted, and reduced from probeset-to gene-level data (taking the maximum value across all samples), with unannotated probesets excluded. The data were row (gene) and column (sample) centred, 76, 77 giving a working dataset of 467 samples and 13 169 unique known genes. Samples were clustered into 'proneural', 'proliferative' or 'mesenchymal' subclasses based upon the relative expression of 323 overlapping genes from the Phillips 6 classifier using Ward's hierarchical clustering. Autophagy-related genes were extracted and investigated for subclass-specific expression correlations using ANOVA, and visualized by boxplots.
Derivation of cultured cells from surgical biopsies
All patients have given informed consent before the surgical intervention. The storage of human tissue is governed by the Human tissue Act (UK; HTA License # 12054). The use of tissue and cells has been approved by the National Hospital Ethics Committee (LREC 08/0077). Neurosurgical biopsies were obtained at the operating theater and immediately transferred into the Department of Neuropathology, where they were dissected for tissue processing into paraffin blocks and subsequent histopathological examination and a further portion was snap frozen. To prepare cells, a third portion was minced as finely as possible, and suspended in cold phosphate-buffered saline (PBS). Erythrocytes were lysed in ACK buffer (Invitrogen, Paisley, UK) when necessary. Tissue fragments were trypsinized, triturated and transferred into six-well plates with medium containing Brain Tumor Initiating Cell permissive medium (DMEM/HamF12, 15 mM Hepes, L-Glutamine, Pen/Strep 10 kU/10 mg/ml), B27 Supplement (Invitrogen17504-044), EGF (recombinant mouse, PeproTech 315 --09 20 ng/ml), bFGF (recombinant human, PeproTech100-18B, 20 ng/ml) For the first week, cells were cultured free floating to form spheres and subsequently transferred into Laminin-coated dishes (Sigma L2020, 0.01 mg/ml, Sigma, Gillingham Dorset, UK) in which they grow adherently. Cell were grown at 95% rH, 20% O 2 and 5% CO 2 .
Cell culture and reagents
Human GSCs and all clones were cultured as described. 44 Briefly, cultured flasks were coated with Laminin (Sigma) for 3 h at 10 mg/ml before to use. GSCs were routinely grown at confluence and then dissociated using Accutase (Sigma). Neurocult NS-A media (stem Cell Technologies, Grenoble, France) is supplemented with the GFs EGF and FGF-2. Human embryonic kidney HEK293T cells were cultured as above in a 5% CO 2 -humidified atmosphere at 37 1C.
Chloroquine (Sigma) was added to the cells for 6 h or 12 h at 10 mM or keep as cotreatment. PI-103 hydrocloride (Tocris Bioscience, Bristol, UK) and MEK inhibitor U0126 (Promega, Southampton, UK) have been added 8 h after the plating and kept overnight at the concentration of 1 mM and 20 mM, respectively.
Cells were normally plated on coverslips coated with laminin or for invading experiments on Oris Collagen I (Platypus Technologies, Oxon, UK).
Invasion and migration assay
In all, 25 Â 10 3 --50 Â 10 3 GSCs were seeded into the upper chamber of BD Bio Coat Matrigel Invasion Chamber in normal media. Cells were left to pass the matrigel chamber for 46 h then fixed in methanol and stained with Hoechst. At least five pictures were taken for each well at Â 10 . Migration was carried using cell culture inserts for 24-well plates, 8.0 mM transparent PET membrane (BDt). Cells were fixed and counted as above. Images were performed on a Zeiss Observer.Z1 inverted microscope (Carl Zeiss Microscopy, Jena, Germany) using a Â 10 objective. Twelve-well alvetex inserts (Cat. No. AVP005-3, Generon, Berkshire, UK) previously coated with Matrigel were used for the detection of endogenous LC3 puncta in G166 cells. In all, 3 Â 10 5 cells were cultured for 1, 3, 7 and 10 days. Alvetex membranes were fixed in 4% paraformaldehyde (weight/volume) and embedded in paraffin. Transverse sections (5 mm) were cut, mounted onto slides and then were dewaxed, rehydrated in graded alcohols, rinsed in distilled water and antigen retrieval-treated for 20 min (10 mM sodium citrate, pH 6.0) in a pressure cooker at 700 W. The sections were washed three times in 1 Â PBS for 10 min each, blocked in 5% goat serum in 0.1% PBS-Tween (vol/vol), incubated overnight with primary antibody, washed three times for 10min each with 1Â PBS, incubated for 1 h with secondary antibody, washed three times with 1 Â PBS and counterstained with DAPI and mounted for confocal microscopy. All imaging was performed on a Zeiss LSM510 confocal microscope using a Â 25 or a Â 63 objective.
Immunofluorescence
For immunocytochemistry experiments cell were fixed with 4% paraformaldehyde in PBS, pH 7.4, for 15 min at room temperature. Excess buffer was drained and the cells were washed three times in PBS. Cells were then permeabilized using 0.1% Triton X-100 in PBS with 5% bovine serum albumin. Fixed cells were incubated with the appropriate primary antibody in PBS with 5% goat serum and 0.1% Triton X-100 overnight at 4 1C. Primary antibody used in this study were: anti-LC3 (Nanotools), anti-p62 (BIOMOL international LP or Santa Cruz). Cells were washed and incubated with antimouse or anti-rabbit Alexa-conjugated antibodies (Invitrogen) for 1 h at room temperature. Coverslips were washed and mounted. All imaging was performed on a Zeiss ObserverZ1 inverted microscope using a Â 100 objective or with a Zeiss LSM700 confocal microscope equipped with a Â 63 objective. Quantification of colocalization was carried out using Volocity 6.0.1 Perkin Elmer software (Perkin Elmer, Waltham, MA, USA).
In vitro scratch wound assay
GSCs were seeded at 2 Â 10 5 in a 24-well ImageLock Microplate and allowed to settle overnight. A single wound was made down the center of each well using the four-pin WoundMaker with 10-ml tip. Wound images are then automatically acquired and registered by the instrument. Data were then analyzed in wound width/time. This metric is calculated by custom algorithms, which are part of the IncuCyte software package (Essen BioScience, Hertfordshire, UK).
Constructs, transfection, lentiviral/retroviral infection DRAM1 (pCMV-SPORT6 4474297) was obtained by Open Biosystem (Thermo scientific, Lafayette, CO, USA) while hRAS-V12 (MSCV hRASv12 IRES GFP 18780) shRNA-expressing vector and GFP-LC3 (pBABEpuro 22405)-expressing vectors were obtained by Addgene (Cambridge, MA, USA). For stable downregulation of ATG5, ATG7, p62 and DRAM1 genes, scrambled and shRNA pGIPZ vectors were purchased from Open Biosystems (Thermo Scientific) or obtained through the Open Biosystems library available at the UCL Cancer Institute. For each, we screened at least five-hairpin sequences and downregulation of these genes was verified by western blot. We chose at least two short hairpins that had the most efficient KD. Lentivirus and retrovirus supernatants were prepared following the manufacturer's instructions and lentiviral infections were carried out accordingly. HEK293T cells were transfected with CalciumPhospate solution (Invitrogen) following the manufacturer's instructions. GST-BHMT plasmid was a kind gift from Patrick B Dennis's lab.
RNA extraction and quantitative real-time PCR Total mRNA was extracted by using the RNAeasy Plus Mini Kit (Qiagen, West Sussex, UK) and tested for purity (A260/280 ratios). cDNA was generated from 4 ml of total RNA by using an oligo-dT primer and the High Capacity RNA-to-cDNA Master Mix for real-time PCR (Applied Biosystem, Carlsbad, CA, USA) according to the manufacturer's instructions. Quantitative real-time PCR was performed using the Mastercycler realplex Human MET primers were designed based on a previous study. 43 Western blot analysis Cells were plated in six-well plates and after each treatment the same number was harvested and lysed directly in Laemmli sample buffer, supplemented with b-mercaptoethanol (Sigma). The proteins separated by SDS --polyacrylamide gel electrophoresis gel electrophoresis, transferred to membrane and then hybridized. Primary antibodies used in this study were as follows: anti-LC3 (Sigma), anti actin (Sigma), anti p62 (BIOMOL international LP and Santa Cruz), anti P-p44/42 MAPK (Thr202/Tyr204) and p44/42 MAPK, anti p-Akt (Ser473) and Akt, anti ATG5 and ATG7, anti GST (all from Cell Signaling, Danvers, MA, USA). We used mainly ECL (Pierce, Thermo Scientific) and when indicated the Odissey imaging system (LI-COR). Secondary antibodies were from Amersham (ECL, Buckinghamshire, UK) or Pierce (Odissey). Quantification of the proteins was carried out using NIH Image J 1.43r software (Wayne Rasband National Institutes of Health, USA, http://rsb.info.nih.gov/ij).
XF24 oxygen consumption analysis and ATP --lactate determination OCR measurements were made using the XF24 Analyzer (Seahorse Bioscience, North Billerica, MA, USA) as described by Guo et al., 46 following the manufacture's instructions. Briefly, cells were seeded at 5 Â 10 4 cells per well in XF24 plates in 100 ml of media and incubated for 12 h prior basal OCR measurements. XF assay medium was low buffered bicarbonate-free DMEM (pH 7.4). Total ATP and lactate levels were measured by plating 1 Â 10 4 cells/ 100 ml on a 96-well plates overnight. Cells were counted and media samples were collected for lactate assay. Total ATP levels were determined using the CellTiter-Glo Luminescent assay (Promega) as per the manufacture's instruction. Lactate was measured using the Trinity Biotech (Co Wicklow, Ireland) lactate assay. Data were expressed as mole of ATP and mg/dl lactate, respectively, and all the values were normalized to cells number.
Mitochondria morphology
Live cells were fluorescently labeled with 25 nM MitoTracker Orange CMXRos (Molecular Probes, Paisley, UK) for mitochondria then fixed and permeabilize for 4 0 ,6-diamidino-2-phenylindole dihydrochloride (Sigma) nuclei detection. All treatments were done according to the manufacturer's instructions. Mitochondrial morphology was analyzed using a Zeiss LSM700 confocal microscope equipped with a Â 63 objective.
Measurement of DC m
For the measurements of DC m , cells were loaded with 50 nM tetramethylrhodamine methylester (TMRM) for 30 min at room temperature and the dye was present during the experiment. TMRM is used in the redistribution mode to assess DC m and therefore a reduction in TMRM fluorescence represents depolarization. 52 Fluorescence measurements were obtained on a confocal microscope (Zeiss 410) equipped with a Â 40 objective.
Autophagy assessment
For quantification of autophagy induction, cells were infected with pBABE-LC3. Where reported, cells were treated with 10 mM CQ before fixation and permeabilize for 4 0 ,6-diamidino-2-phenylindole dihydrochloride (Sigma) nuclei detection. Images were analyzed at Â 100 or Â 63. A minimum of 100 cells was scored for each condition in three replicate experiments. The percentage of cells expressing GFP-LC3 puncta was quantified by determining the number of cells displaying punctate out of a population of 100 fluorescent cells replicated in three independent experiments, or number of puncta per cell was shown. 
